Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis | 3 |
Abstract | 3 |
Introduction | 3 |
Methods | 4 |
Serum proteome signature of SSc-PAH | 4 |
Study population | 4 |
SOMAscan assay | 4 |
ELISA assays | 4 |
Statistical analyses | 4 |
Chemerin/CMKLR1 axis and pulmonary vascular remodelling | 5 |
Study population | 5 |
Single-cell RNA sequencing in explanted human lungs | 5 |
Data generation | 5 |
Data analysis | 5 |
Confocal immunofluorescence analyses in explanted human lungs | 5 |
Role of CMKLR1 in the proliferation of human PA-SMCs | 5 |
PA-SMC proliferation experiments | 5 |
Descriptive analysis | 5 |
Results | 5 |
Serum levels of chemerin are elevated and correlate with PVR in SSc-PAH patients | 5 |
Expression of chemerin receptor CMKLR1 is increased on PA-SMCs from SSc-PAH patients | 6 |
The SSc-PAH serum-induced PA-SMC proliferation seems inhibited by a chemerin-CMKLR1 inhibitor | 7 |
Discussion | 7 |
Chemerin as a surrogate marker for haemodynamic severity in SSc-PAH | 7 |
Chemerin as a contributor to the pathogenesis of SSc-PAH | 8 |
Strengths and limitations | 9 |
Conclusions | 10 |
References | 10 |
Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases | 18 |
Abstract | 18 |
Introduction | 18 |
Methods | 19 |
Study population and patient identification | 19 |
Patient recruitment for prospective study | 19 |
Data Collection | 19 |
Exposure of interest | 19 |
Outcome assessments | 19 |
Statistical analysis | 19 |
Patient and public involvement | 20 |
Results | 20 |
Participant characteristics | 20 |
Postacute sequelae according to breakthrough infection status | 20 |
Acute COVID-19 symptoms and clinical course according to breakthrough infection status | 20 |
Patient-reported outcomes including pain, fatigue, functional status and rheumatic disease activity following COVID-19 infection | 22 |
Discussion | 23 |
References | 26 |
Novel aspects in the pathophysiology and diagnosis of glomerular diseases | 44 |
Abstract | 44 |
Introduction | 44 |
Clinical phenotypes | 44 |
IgA vasculitis | 45 |
LN in systemic lupus erythematosus | 45 |
Cryoglobulinaemic glomerulonephritis | 47 |
Anti-GBM disease | 47 |
ANCA-associated vasculitis | 48 |
Circulating immune complexes and location of immune deposits/complexes within glomerular structures | 48 |
How do immune complexes/cells damage the kidney? | 48 |
Presence of immune deposits/complexes and prognostication/therapeutic response | 49 |
New therapeutic avenues | 50 |
Conclusion | 50 |
References | 50 |
Powered by FlippingBook